NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout

    India
    Business
    World
    Politics
    Sports
    Technology
    Entertainment
    Auto
    Lifestyle
    Inspirational
    Career
    Bengaluru
    Delhi
    Mumbai

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
    Home / News / Business News / Nirma acquires stake worth Rs. 5,651cr in Glenmark Life Sciences
    Next Article
    Nirma acquires stake worth Rs. 5,651cr in Glenmark Life Sciences
    The transaction will help strengthen Glenmark Pharma's balance sheet by extinguishing debt

    Nirma acquires stake worth Rs. 5,651cr in Glenmark Life Sciences

    By Rishabh Raj
    Sep 22, 2023
    03:03 pm

    What's the story

    Glenmark Pharmaceuticals has agreed to sell a 75% stake in its subsidiary, Glenmark Life Sciences, to Nirma for Rs. 5,651 crore.

    The deal values Glenmark Life Sciences at Rs. 7,535.4 crore and will leave Glenmark Pharma with a 7.84% stake in the company.

    The transaction is subject to regulatory and shareholder approvals, and Nirma will make a mandatory open offer to public shareholders for an additional 17.15% stake at Rs. 631 per share.

    What Next?

    Glenmark Pharma's FY23 figures

    GLS recorded FY23 revenues of Rs. 2,161 crore with a net profit of Rs. 467 crore.

    The transaction is pending customary closing conditions, including regulatory and shareholder approvals.

    Kotak Investment Banking served as Glenmark Pharma and GLS's exclusive financial advisor, while S&R Associates provided legal advice to Glenmark Pharma, and Trilegal advised GLS, according to a transaction update.

    Insights

    Glenmark Pharma's balance sheet strengthened by the deal

    The transaction will help strengthen Glenmark Pharma's balance sheet by extinguishing debt, making the company net cash positive after the deal's completion.

    Yasir Rawjee, Managing Director and CEO of Glenmark Life Sciences said, "We will continue to operate as an independent API (active pharmaceutical ingredient) company under the new ownership of Nirma Limited."

    Glenmark Pharma does not expect changes in GLS management post-deal, and both companies have agreed to non-compete and non-solicit arrangements for a specified period.

    Details

    A look at Glenmark Pharma's stock prices

    Following this news, Glenmark Pharma's stock price dropped by more than 6% in early trading on NSE on September 22.

    The stock opened at Rs. 805, down from the previous day's close of Rs. 827.70, and declined by 6.36% to reach Rs. 775 on NSE during today's trading session.

    As of the time of writing, the stock was trading at Rs. 803.05, down 2.92%.

    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    Latest
    Stock Market

    Latest

    Is a documentary being made on Ram Charan? Madame Tussauds
    Allahabad HC dismisses Elvish Yadav's plea in snake venom case Allahabad High Court
    PSL 2025 set to resume in Pakistan this week: Details Pakistan Cricket Board
    What are Pakistan's Kirana Hills—which came up during DGMO briefing  Punjab

    Stock Market

    JFSL shares surge for 2nd straight session amid promoter purchases Reliance Industries
    Sensex and Nifty close flat, mid-cap indices show bullish signals Sensex
    Hindenburg reacts to OCCRP allegations against Adani, says 'loop closed' Adani Group
    Sensex slips over 250 points, Nifty settles above 19,250 mark Sensex
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2025